TransMedics Revenue and Competitors
Estimated Revenue & Valuation
- TransMedics's estimated annual revenue is currently $155.7M per year.
- TransMedics received $12.5M in venture funding in July 2016.
- TransMedics's estimated revenue per employee is $351,400
- TransMedics's total funding is $266M.
Employee Data
- TransMedics has 443 Employees.
- TransMedics grew their employee count by 82% last year.
TransMedics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CFO | Reveal Email/Phone |
2 | VP | Reveal Email/Phone |
3 | VP Abdominal Medical Affairs | Reveal Email/Phone |
4 | VP Clinical Affairs | Reveal Email/Phone |
5 | SVP, Global Regulatory Affairs | Reveal Email/Phone |
6 | Controller | Reveal Email/Phone |
7 | VP Cardiothoracic Clinical Development | Reveal Email/Phone |
8 | VP, Corporate Controller | Reveal Email/Phone |
9 | VP Human Resources | Reveal Email/Phone |
10 | Sr. Director, Data Management and Biostatistics | Reveal Email/Phone |
TransMedics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $9.8M | 39 | 3% | N/A | N/A |
#2 | $8.5M | 34 | 3% | N/A | N/A |
#3 | $3M | 12 | -29% | N/A | N/A |
#4 | $5630M | 7477 | -11% | $450M | N/A |
#5 | $4.5M | 18 | 6% | N/A | N/A |
#6 | $7.2M | 57 | 27% | $29.6M | N/A |
#7 | $14.3M | 57 | -12% | N/A | N/A |
#8 | $2.3M | 18 | 6% | $44M | N/A |
#9 | $40.7M | 162 | -1% | N/A | N/A |
#10 | $45.7M | 182 | -5% | N/A | N/A |
What Is TransMedics?
TransMedics Inc. is the world's leader in portable ex-vivo perfusion and assessment of donor organs for transplantation. The company was founded to address the need for more and better organs for transplantation, and is focused on transforming the standard of care increasing organ utilization, improving patient outcomes, and reducing transplant costs throughout the heath care system. The OCS Lung and OCS Heart systems are CE-marked and in commercial use outside the US, and are currently being reviewed by the FDA for U.S. market access. The OCS Liver is in an FDA pivotal trial (The OCS Liver PROTECT Trial) in the United States and a CE-Mark trial in (The REVIVE Trial) in Europe.
keywords:Biotechnology,Hardware,Healthcare,Medical Devices,Pharmaceuticals
$266M
Total Funding
443
Number of Employees
$155.7M
Revenue (est)
82%
Employee Growth %
N/A
Valuation
N/A
Accelerator
TransMedics News
TransMedics (Nasdaq:TMDX) announced today that it received FDA premarket approval (PMA) for its OCS Heart system. FDA PMA allows Andover,...
TransMedics Group (NASDAQ:TMDX) said the U.S. Food and Drug Administration (FDA) granted premarket approval (PMA) to its OCS Heart System...
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in...
ANDOVER, Mass., Nov. 9, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended Septe ...
ANDOVER, Mass., Nov. 4, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced positive topline results from its OCS donors ...
Other Companies in Andover
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $101.3M | 463 | 8% | N/A |
#2 | $133.4M | 508 | -14% | N/A |
#3 | $35M | 548 | 9% | N/A |
#4 | $125.6M | 558 | N/A | N/A |
#5 | $136.1M | 605 | 4% | N/A |
TransMedics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2004-01-14 | $26.3M | B | Article | |
| 2006-03-15 | $29.8M | C | 3i Group | Article |
| 2007-03-14 | $25.0M | D | Article | |
| 2009-07-18 | $2.5M | Undisclosed | Article | |
| 2009-12-10 | $0.0M | Undisclosed | Article | |
| 2010-03-05 | $36.0M | Undisclosed | Foundation Capital , Kleiner Perkins Caufield & Bye | Article |
| 2012-11-28 | $36.0M | Undisclosed | Abrams Capital | Article |
| 2015-06-08 | $20.0M | Undisclosed | Article | |
| 2016-05-27 | $51.2M | Undisclosed | Fayerweather Fund | Article |
| 2016-07-14 | $12.5M | Undisclosed | Fayerweather Fund | Article |